With the $135.11/share all-cash acquisition by AbbVie pending close in Q3 2026, APGE shares are essentially locked near the deal price. The primary trading consideration is the merger arbitrage spread and any regulatory/special meeting timing updates. Watch for shareholder vote date and FTC review. The standalone pipeline milestones (Phase 3 AD, EoE, asthma) are now AbbVie's story.
Price Chart
Executive Summary
Apogee reported Q2 2026 financial results amid a transformational period: positive Phase 2 APEX Part B data for lead asset zumilokibart, a $1.3B non-dilutive financing collaboration with Blackstone Life Sciences, and the pending $10.9B acquisition by AbbVie at $135.11/share. Net loss widened to $85.9M from $66.1M YoY on higher R&D spend, but the acquisition agreement caps the stock near the deal price, rendering the earnings miss immaterial for current holders.
Key Facts
- AbbVie to acquire Apogee for $135.11 per share in cash, total equity value ~$10.9 billion.
- Blackstone Life Sciences provided up to $1.3B in non-dilutive capital to support zumilokibart Phase 3 and commercialization.
- Phase 2 APEX Part B met all primary/secondary endpoints: 65.9% EASI-75 (41.9% placebo adjusted), supporting mid-dose for Phase 3 initiation in 2H 2026.
- Expansion trials announced: ELEVATE Phase 2a in EoE (2H 2026) and ASPIRE Phase 2b registrational asthma trial (1H 2027).
- Cash position $1.3B as of June 30, 2026, extending runway into 2029.
- Q2 2026 net loss of $85.9M vs $66.1M YoY; R&D expenses $67.3M vs $55.7M YoY.
- Revenue share liability of ~$99.2M recorded related to the Blackstone financing.
- Transaction expected to close in Q3 2026, subject to shareholder and regulatory approvals.
Financial Impact
Acquisition valued at ~$10.9B total equity; Blackstone financing up to $1.3B non-dilutive capital; net loss of $85.9M in Q2 2026.
Risk Factors
- Transaction may fail to close due to regulatory hurdles or failure to obtain shareholder approval; break fee and litigation risk exist.
- Zumilokibart Phase 3 results may not replicate Phase 2 efficacy; pipeline-expansion data (EoE, asthma) face clinical risk under AbbVie.
- Expenses continuing to increase without revenue; business reliant on financing and acquisition proceeds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341239 |
| Document: apge-20260810.htm | 0001193125-26-341239 |
| Document: 0001193125-26-341239-index-headers.html | 0001193125-26-341239 |
| Document: 0001193125-26-341239-index.html | 0001193125-26-341239 |
| Document: 0001193125-26-341239.txt | 0001193125-26-341239 |
| 8-K Data (Synthetic) | 0001193125-26-341239 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access